Revvity (RVTY) shares advanced Monday after the medicalও equipment maker formerly known as PerkinElmer posted better-than-expected results and boosted its profit guidance𒐪 on higher demand for its diagnostic products.

The company reported second-quarter adjusted operating 澳洲幸运5开奖号码历史查询:earnings per share (EPS) of $1.22, $0.10 more than the average estimate of analysts surveyed by Visible Alpha. Revenue fell 2.5% year-over-year to $691.7 million, but it was also more than forecasts. 

Sales in its Diagnostic unit rose 1.4💧% to $378.0 million. However, Life Sciences segment sales declined 6.7% to $313.8 million.

CEO Says Revvity 'On a Good Trajectory'

CEO Prahlad Singh said the results put Revvity "on a good trajectory towards achieving our full-year goals."

The company increased its 2024 adjusted EPS outlook to $4.70 to $4.80 from the earlier guidance of $4.55 to $4.75. It narrowed its outlook for revenue to $2.77 billion to $2.79 billion from $2.76 billion to $2.82 billion.

Revvity shares rose 3.5% as of 10:45 a.m. ET Monday to $119.18, their highest level in almost a year.